Sorry, this activity has expired and is no longer available for CME credit. You may still enjoy the program.
CME Information
Sponsorship Statement: This continuing medical education
activity is sponsored by 
Title: AMD: Examining the Evidence and
Implementing Effective Treatment Strategies into Practice
Learning Objectives: At the conclusion of this
activity participants should be able to:
- Discuss VEGF activity as it occurs in normal physiology and in
disease states such as AMD.
- Identify emerging monotherapy and combination treatment strategies
for age-related macular degeneration.
Course Chair:
Carmen A. Puliafito,
MD, MBA
Retina/Vitreous Section Editor
Ocular Surgery News®
Dean, Keck School of Medicine
Professor of
Ophthalmology
and Health Management
May S. and John Hooval Dean’s
Chair in Medicine
University of Southern California
Los Angeles,
California
Faculty:
Scott W. Cousins,
MD
Robert Machemer, MD Professor of Ophthalmology and
Immunology
Vice Chair for Research
Department of Ophthalmology
Director, Duke Center for Macular Diseases
Duke University
Durham,
NC
Title: Controversies in the Use of Anti-VEGF for
Neovascular AMD: Utilization Patterns and Safety Issues
Victor H. Gonzalez, MD
Private Practice
McAllen, TX
Title: Applying the Results from Recent Clinical Trials
to Everyday Practice
Continuing Medical Education Information:
Vindico Medical Education is
accredited by the Accreditation Council for Continuing Medical Education to
provide continuing medical education for physicians.
Vindico Medical Education designates this enduring material for
a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
This enduring material is approved for 1 year from the date of original
release, April 14, 2011 to April 13, 2012.
How To Participate in this Activity and Obtain CME
Credit:
To participate in this CME activity, you must read the
objectives, answer the Pretest questions, watch and listen to the
presentations, complete the Posttest, and complete the evaluation. Provide only
one (1) correct answer for each question. A satisfactory score is defined as
answering 2 out of 2 of the Posttest questions correctly. Upon receipt of the
completed materials, if a satisfactory score on the Posttest is achieved,
Vindico Medical Education will issue an AMA PRA Category 1
Credit(s)TM certificate.
Faculty:
Carmen A. Puliafito, MD, MBA
Scott W. Cousins, MD
Victor H. Gonzalez, MD
Peer Reviewer:
William Lloyd, MD
Disclosures:
In accordance with the
Accreditation Council for Continuing Medical Education’s Standards for
Commercial Support, all CME providers are required to disclose to the activity
audience the relevant financial relationships of the planners,
teachers, and authors involved in the development of CME content. An individual
has a relevant financial relationship if he or she has a financial relationship
in any amount occurring in the last 12 months with a commercial interest whose
products or services are discussed in the CME activity content over which the
individual has control. Relationship information appears on this page and the
next page.
The authors disclose that they do have significant financial interests
in any products or class of products discussed directly or indirectly in this
activity, including research support.
Faculty members report the following relationship(s):
Carmen A. Puliafito, MD, MBA
Consultant: Zeiss Meditec
Scott W. Cousins, MD
Salary: Duke
Consulting
Fees: Eyetech, Inc., Genentech
Victor H. Gonzalez, MD
Consulting Fees: Eyetech,
Inc., Genentech, Regeneron
Fees for Non-CME Services: Eyetech, Inc.,
Genentech, ISTA Pharmaceuticals
Contracted Research: Eyetech, Inc.,
Genentech, Regeneron
Peer reviewer reports the following relationship(s):
William Lloyd, MD (an employee of Vindico Medical
Education)
No relevant financial relationships to disclose.
Vindico Medical Education staff report
the following relationship(s):
No relevant financial relationships to
disclose.
Signed disclosures are on file at Vindico Medical Education, Office of
Medical Affairs and Compliance.
Overview: Anti-VEGF medications have been shown
to be effective in stopping progression, and in some cases improve vision, in
patients with wet age-related macular degeneration. There is increasing
evidence that these agents may also be effective in treating diabetic macular
edema. Clinicians will discuss current clinical trials and other data showing
the efficacy of this class of medications, as well as lay out the theory and
data on combining these agents with other treatment modalities to take
advantage of multiple mechanisms of action.
Target Audience: The intended learners for this
activity are vitreoretinal specialists, comprehensive ophthalmologists, and
other healthcare professionals involved in the treatment of patients with
vitreoretinal disorders.
Unlabeled and Investigational Usage:
The
audience is advised that this continuing medical education activity may contain
references to unlabeled uses of FDA-approved products or to products not
approved by the FDA for use in the United States. The faculty members have been
made aware of their obligation to disclose such usage. All activity
participants will be informed if any speakers/authors intend to discuss either
non-FDA approved or investigational use of products/devices.
Copyright Statement:
Created and published
by Slack Incorporated®, 6900 Grove Road, Building 100, Thorofare, NJ
08086-9447. Telephone: 856-848-1000; Fax: 856-848-6091. Printed in the USA.
Copyright© 2011 Slack Incorporated®. All rights reserved. No part of
this publication may be reproduced without written permission from the
publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not
necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial
products, or manufacturers. The faculty/authors may discuss the use of
materials and/or products that have not yet been approved by the US Food and
Drug Administration. All readers and continuing education participants should
verify all information before treating patients or utilizing any product.